About us Contacts Drug interactions: 390 212
Drug search by name

Kaletra and Osimertinib

Determining the interaction of Kaletra and Osimertinib and the possibility of their joint administration.

Check result:
Kaletra <> Osimertinib
Relevance: 06.08.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Ritonavir may significantly increase the blood levels of osimertinib. This may increase the risk and/or severity of side effects such as nausea, diarrhea, mouth sores, heart muscle problems (e.G., heart failure), and an irregular heart rhythm that may be serious and potentially life-threatening. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the interaction, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, swelling, or heart palpitations during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of osimertinib, which has been shown in vitro to be primarily metabolized by the isoenzyme. However, no pharmacokinetic data are available from drug interaction studies. Because osimertinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.

MANAGEMENT: Concomitant use of osimertinib with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, close monitoring for adverse effects such as diarrhea, QT prolongation, torsade de pointes arrhythmia, and cardiomyopathy (e.g., cardiac failure, pulmonary edema, ejection fraction decreases) is recommended, and the osimertinib dosage adjusted accordingly or treatment discontinued as necessary.

References
  • "Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.
Kaletra

Generic Name: lopinavir / ritonavir

Brand name: Kaletra

Synonyms: n.a.

Osimertinib

Generic Name: osimertinib

Brand name: Tagrisso

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction